Canadian HS Clinical Trials
Alberta
Alberta DermaSurgery Centre
Phase III – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa. For more information contact us at rebecca@raoderm.com or 587-487-0187 or fax 780-437-2247. Address: Suite 300, 7609 109 Street NW, Edmonton, Alberta, T6G 1C3, Canada
Beacon Dermatology
Phase III – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa. For more information contact us at maha@beaconderm.com or 587-351-3025 or fax 587-392-7544. Address: 3110 17 Avenue SW, Suite 201, Calgary, Alberta, T3E 0B2, Canada
Beacon Dermatology
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at maha@beaconderm.com or 587-351-3025 or fax 587-392-7544. Address: 3110 17 Avenue SW, Suite 201, Calgary, Alberta, T3E 0B2, Canada
Dermatology Research Institute
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at hello@dermatologyresearch.ca or 403-263-3376 or fax 403-536-2403. Address: Meadows Mile Professional Building, Suite 310, 8500 Blackfoot Trail SE, Calgary, Alberta, T2J 7E1, Canada
British Columbia
Dr. Chih-ho Hong Medical Inc.
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at 604-953-1333 or fax 604-953-1334. Address: 15300 105 Avenue, Suite 20, Surrey, British Columbia, V3R 6A7, CanadaEnverus Medical Research
Phase III – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa. For more information contact us at gurjind@enverusmedical.com or 604-495-8278 or fax 604-495-8275. Address: 13737 96 Avenue, Suite 603, Surrey, British Columbia, V3V 0C6, CanadaEnverus Medical Research
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at gurjind@enverusmedical.com or 604-495-8278 or fax 604-495-8275. Address: 13737 96 Avenue, Suite 603, Surrey, British Columbia, V3V 0C6, CanadaManitoba
Wiseman Dermatology Research Inc.
Phase III – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa. For more information contact us at studycoordinator@skinwise.ca or 204-943-4922 or fax 204-942-0789. Address: 6-1170 Taylor Avenue, Winnipeg, Manitoba, R3M 3Z4, Canada
Wiseman Dermatology Research Inc.
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at studycoordinator@skinwise.ca or 204-943-4922 or fax 204-942-0789. Address: 6-1170 Taylor Avenue, Winnipeg, Manitoba, R3M 3Z4, Canada
New Brunswick
Brunswick Dermatology Center
Phase III – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa. For more information contact us at clinicaltrials.bdc@gmail.com or 506-459-1808 or fax 506-459-1818. Address: 204 Brunswick Street, Fredericton, New Brunswick, E3B 1G9, Canada
Wiseman Dermatology Research Inc.
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at studycoordinator@skinwise.ca or 204-943-4922 or fax 204-942-0789. Address: 6-1170 Taylor Avenue, Winnipeg, Manitoba, R3M 3Z4, Canada
Ontario
DermEffects
Phase II – A randomized, double-blind, placebo-controlled, proof-of-concept study assessing the efficacy and safety of anti-TNF-OX40L NANOBODY molecule, SAR442970, in participants with moderate to severe hidradenitis suppurativa. For more information contact us at dermeffects2@gmail.com or 519-204-6868 / 519-472-8686 or fax 519-472-8484. Address: 1560 Hyde Park Road, London, Ontario, N6H 5L5, Canada
Brunswick Dermatology Center
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at dermeffects2@gmail.com or 519-204-6868 / 519-472-8686 or fax 519-472-8484. Address: 1560 Hyde Park Road, London, Ontario, N6H 5L5, Canada
Brunswick Dermatology Center
Phase III – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa. For more information contact us at dermeffects2@gmail.com or 519-204-6868 / 519-472-8686 or fax 519-472-8484. Address: 1560 Hyde Park Road, London, Ontario, N6H 5L5, Canada
Dr. S. K. Siddha Medicine Professional Corporation
Phase II – A randomized, double-blind, placebo-controlled, proof-of-concept study assessing the efficacy and safety of anti-TNF-OX40L NANOBODY molecule, SAR442970, in participants with moderate to severe hidradenitis suppurativa. For more information contact us at 905-235-5232 / 905-235-5231 or fax 519-472-8484. Address: 679 Davis Drive, Suites 205 and 210, Newmarket, Ontario, L3Y 5G8, Canada
Dr. S. K. Siddha Medicine Professional Corporation
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at 905-235-5232 / 905-235-5231 or fax 519-472-8484. Address: 679 Davis Drive, Suites 205 and 210, Newmarket, Ontario, L3Y 5G8, Canada
Dr. S. K. Siddha Medicine Professional Corporation
Phase III – Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. For more information contact us at 905-235-5232 / 905-235-5231 or fax 519-472-8484. Address: 679 Davis Drive, Suites 205 and 210, Newmarket, Ontario, L3Y 5G8, Canada
Guelph Dermatology Research
Phase III – Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. For more information contact us at guelphdermresearch@gmail.com
or 519-836-8558 ext. 5 or fax 519-822-0403. Address: 33 Farley Drive, Unit 8, Guelph, Ontario, N1L 0B7, Canada
LEADER Research
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at 289-812-0046 or fax 289-780-0497. Address: 928 Barton Street East, Hamilton, Ontario, L8L 3C3, Canada
LEADER Research
Phase II – A Phase 2, randomized, double-blind, plcaebo-controlled, parallel group, proof-of-concept study assessing the efficacy and safety of amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. For more information contact us at 289-812-0046 or fax 289-780-0497. Address: 928 Barton Street East, Hamilton, Ontario, L8L 3C3, Canada
Lynderm Research Inc.
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at anosha@lynderma.com
or 905-471-8011 or fax 905-471-8182. Address: 25 Main Street Markham North, Markham, Ontario, L3P 1X3, Canada
Research Toronto
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at research@dermonbloor.com
or 416-962-0123 or fax 416-962-8227. Address: 34 Park Road, Toronto, Ontario, M4W 2N4, Canada
SimcoDerm Medical and Surgical Dermatology Center
Phase II – A randomized, double-blind, placebo-controlled, proof-of-concept study assessing the efficacy and safety of anti-TNF-OX40L NANOBODY molecule, SAR442970, in participants with moderate to severe hidradenitis suppurativa. For more information contact us at trials@simcoderm.com or 647-202-6393or fax 705-503-6330. Address: 5 Quarry Ridge Road, Suite 105, Barrie, Ontario, L4M 7G1, Canada
SimcoDerm Medical and Surgical Dermatology Center
Phase II – A Phase 2, randomized, double-blind, plcaebo-controlled, parallel group, proof-of-concept study assessing the efficacy and safety of amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. For more information contact us at trials@simcoderm.com or 647-202-6393or fax 705-503-6330. Address: 5 Quarry Ridge Road, Suite 105, Barrie, Ontario, L4M 7G1, Canada
SimcoDerm Medical and Surgical Dermatology Center
Phase III – Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.. For more information contact us at trials@simcoderm.com or 647-202-6393 or fax 705-503-6330. Address: 5 Quarry Ridge Road, Suite 105, Barrie, Ontario, L4M 7G1, Canada
SimcoDerm Medical and Surgical Dermatology Center
Phase III – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa. For more information contact us at trials@simcoderm.com or 647-202-6393 or fax 705-503-6330. Address: 5 Quarry Ridge Road, Suite 105, Barrie, Ontario, L4M 7G1, Canada
SKiN Centre for Dermatology
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at mfisher@centrefordermatology.com or 705-874-1533 or fax 705-874-0855. Address: 775 Monaghan Road, Peterborough, Ontario, K9J 5K2, Canada
Saskatchewan
Skinsense Medical Research
Phase III – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. For more information contact us at skinsenseresearch@gmail.com or 306-644-7546 option 1 or fax 306-664-7547. Address: 411 2nd Avenue North, Suite 2, Saskatoon, Saskatchewan, S7K 2C1, Canada
The Dermatology Association of Ontario is pleased to offer members the opportunity to list their actively recruiting clinical trials for recruitment purposes. For information on how to submit a trial, click here.
The studies listed below are currently recruiting prospective patients. Clinical trials may have additional eligibility requirements not listed here. Contact the location directly for more information and to inquire about eligibility.
Abdominal subcutaneous fat reduction
Bertucci Medspa – Now recruiting ages 18 to 64 with moderate to severe abdominal fat. For more information contact us at (905) 850-4415 or crc@bertuccimedspa.com
Acne Scarring
Bertucci Medspa – Recruiting for patients 18+ with moderate to severe atrophic acne scars. Please contact us at 905-850-4415 or crc@bertuccimedspa.com
The Centre for Clinical Trials – Now recruiting ages 18+ with moderate to severe Acne Scarring. For more information contact clinicaltrials@icls.ca.
The Centre for Dermatology – Now recruiting ages 18 and over with moderate to severe acne scarring. For more information please contact 905-889-2019 or s.dyalsingh@tcfd.ca
Alopecia Areata
Lynderm Research INC, Markham ON – Now recruiting ages 12 to 70 years old with moderate severe Alopecia Areata. For more information please contact 905-871-8011 or andreaa@lynder.com
Atopic Dermatitis
AvantDerm – Now recruiting ages 18 and over with moderate to severe Atopic Dermatitis. For more information please contact 416-891-3376 or upandit@avantderm.com
AvantDerm – Now recruiting ages 18 and over with moderate to severe Atopic Dermatitis previously treated with Dupilumab. For more information please contact 416-891-3376 or upandit@avantderm.com
CCA Medical Research Corporation – Now recruiting ages 18 and over with moderate to severe Atopic Dermatitis. For more information please 647-855-8117
Dermedge Research Inc. – Now recruiting ages >12-18 and 18+ with moderate to severe Atopic Dermatitis. For more information, please contact atopicdermatitistrials@dermedge.com, or 905-274-9999 ext. 106.
Leader RESEARCH, Hamilton ON – Now recruiting ages 12-80 with moderate to severe Atopic Dermatitis. For more information please contact contact@leaderresearch.ca or 289-812-0046
Leader RESEARCH, Hamilton ON – Now recruiting ages 18 and over with moderate to severe Atopic Dermatitis. For more information please contact contact@leaderresearch.ca or 289-812-0046
Leader RESEARCH, Hamilton ON – Now recruiting ages 18 and over with moderate to severe Atopic Dermatitis with previous exposure to Dupilumab. For more information please contact contact@leaderresearch.ca or 289-812-0046
Lovegrove Dermatology – Now recruiting ages 6 and over with moderate to severe Atopic Dermatitis. For more information please contact research@lovederm.ca or 519-204-3959
Lynderm Research INC, Markham ON – Recruiting 12-17 years old for Moderate to Severe Atopic Dermatitis. Contact us at 905-871-8011 or andreaa@lynderma.com
Lynderm Research INC, Markham ON – Recruiting 18 to 75 years old for Moderate to Severe Atopic Dermatitis. Contact us at 905-871-8011 or andreaa@lynderma.com
North York Research Inc. – Now recruiting ages 18 and over with moderate to severe Atopic Dermatitis. For more information please contact 416-222-2204 or anas@bnderm.com
The Centre for Clinical Trials, Oakville, ON – Now recruiting ages 18 and over with moderate to severe Atopic Dermatitis. For more information contact clinicaltrials@icls.ca
The Centre for Clinical Trials, Oakville, ON – Now recruiting ages 18+ with moderate to severe Atopic Dermatitis. For more information contact clinicaltrials@icls.ca
The Centre for Dermatology – Now recruiting ages 18 and over for Moderate to Severe Atopic Dermatitis. For more information contact 905-889-2019 or s.dyalsingh@tcfd.ca
Chronic Inducible Uritcaria
Leader RESEARCH, Hamilton ON – Now recruiting ages 18 and over with moderate to severe Chronic Inducible Uritcaria. For more information please contact contact@leaderresearch.ca or 289-812-0046
Chronic Pruitis
Lynderm Research INC, Markham ON – Recruiting 18-90 years old for Moderate to Severe Chronic Pruritis. Contact us at 905-471-8011 or devya@lynderma.com
Chronic Spontaneous Urticaria
Leader RESEARCH, Hamilton ON – Recruiting patients ages 18 and older with Chronic Spontaneous Urticaria. Contact us at contact@leaderresearch.ca or 289-812-0046
Lynderm Research INC, Markham ON – Recruiting patients 6-80 years old with Moderate to Severe Chronic Spontaneous Urticaria. Contact us at 905-471-8011 or devya@lynderma.com.
Dermatitis
Oak Ridges Aesthetics Centre – Now recruiting ages 18 and over with moderate to severe Dermatitis. For more information please contact info@ordc.ca
Oak Ridges Aesthetics Centre – Now recruiting ages 12 and over with moderate to severe Dermatitis. For more information please contact info@ordc.ca
Discoid Lupus Erythematosus
North York Research Inc. – Now recruiting ages 18 to 75 with moderate to severe Discoid Lupus Erythematosus. For more information please contact 416-222-2204 or anas@bnderm.com
Hidradenitis Suppurativa
Lynderm Research INC, Markham ON – Now recruiting patients aged 12+ with Moderate to Severe Hidradenitis Suppurativa. Please contact us at 905-871-8011 or andreaa@lynderma.com
Non-Segmental Vitiligo
North York Research Inc. – Now recruiting ages 18 and over with Non-Segmental Vitiligo. For more information please contact 416-222-2204 or anas@bnderm.com
Plaque Psoriasis
Leader RESEARCH, Hamilton ON – Now recruiting ages 18-70 with moderate to severe Plaque Psoriasis. For more information please contact contact@leaderresearch.ca or 289-812-0046
Leader RESEARCH, Hamilton ON – Now recruiting ages 18 and over with moderate to severe Plaque Psoriasis. For more information please contact contact@leaderresearch.ca or 289-812-0046
Lovegrove Dermatology – Now recruiting ages 18 and over with moderate to severe Plaque Psoriasis. For more information please contact research@lovederm.ca or 519-204-3959
North York Research Inc. – Now recruiting ages 18 and over with moderate to severe Plaque Psoriasis. For more information please 416-222-2204 or anas@bnderm.com
The Centre for Clinical Trials – Now recruiting ages 18 and over with moderate to severe Plaque Psoriasis. For more information please contact clinicaltrials@icls.ca
Prurigo Nodularis
CCA Medical Research Corporation – Now recruiting ages 18 and over with moderate to severe Prurigo Nodularis. For more information please contact 647-855-8117
Lynderm Research INC, Markham ON – Now recruiting patients 18+ with Mild to Severe Prurigo Nodularis. Please contact us at 905-871-8011 or andreaa@lynderma.com
North York Research Inc. – Now recruiting ages 18 and over with Prurigo Nodularis. For more information please contact 416-222-2204 or anas@bnderm.com
Psoriasis
CCA Medical Research Corporation – Now recruiting ages 18 and over with moderate to severe Psoriasis. For more information please contact 647-855-8117
Dermedge Research Inc. – Now recruiting ages >12-18 and 18+ with moderate to severe Psoriasis. For more information, please contact psoriasistrials@dermedge.com, or 905-274-9999 ext. 106
Lynderm Research INC, Markham ON – Now recruiting patients 2-17 years old with Moderate to Severe Psoriasis. Please contact us at 905-871-8011 or andreaa@lynderma.com
Lynderm Research INC, Markham ON – Now recruiting patients 18+ years old with Moderate to Severe Psoriasis. Please contact us at 905-871-8011 or andreaa@lynderma.com
The Centre for Dermatology – Now recruiting ages 18 and over with moderate to severe Psoriasis. For more information please contact s.dyalsingh@tcfd.ca or 905-889-2019
Psoriatic Arthritis
Lynderm Research INC, Markham ON – Now recruiting patients 18+ with Moderate to Severe Psoriatic Arthritis. Please contact us at 905-471-8011 or devya@lynderma.com
Subcutaneous Abdominal Fat
The Centre for Dermatology – Now recruiting ages 18 to 64 with moderate to severe Subcutaneous Abdominal Fat. For more information please contact 905-889-2019 or s.dyalsingh@tcfd.ca
Vitiligo
Dermedge Research Inc. – Now recruiting ages >12-18 and 18+ with moderate to severe Vitiligo. For more information, please contact vitiligotrials@dermedge.com, or 905-274-9990 ext. 106
Lynderm Research Inc., Markham, Ontario – Recruiting for patients 18+ years old with Mild to Severe Vitiligo. Please contact 905-871-8011 OR andreaa@lynderma.com
The Centre for Clinical Trials, Oakville, ON – Now recruiting ages 18 and older with nonsegmental Vitiligo. For more information please contact clinicaltrials@icls.ca
